What is SPRY's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.42B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SPRY?

P/E (TTM) is n/a and 52-week range is $3.98 to $13.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SPRY figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SPRY?

The company profile lists revenue (TTM) near $117M, net income (TTM) near $-21.54B, EPS (TTM) near $-2.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ARS Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 99.3M shares outstanding, ISIN US82835W1080 when available from company profile and filing metadata.

ARS Pharmaceuticals Inc

$SPRY

Health Care · Biotechnology

IR Run Scenarios

$4.23

-7.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 158 full-time employees. The company went IPO on 2020-12-04. The firm is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. The company is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.

Employees

158

Website

ars-pharma.com/

IPO

2020-12-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)